Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The Company’s product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, received approval from the United States Food and Drug Administration. The Company has active clinical development programs in multiple therapeutic areas such as nephropathic cystinosis, nonalcoholic fatty liver disease, Huntington’s disease (HD), and Leigh syndrome and other mitochondrial disease. The Company’s preclinical programs consist of HepTide and ADO (cysteamine dioxygenase).